Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
2001 1
2004 1
2006 3
2007 5
2008 4
2009 4
2010 9
2011 2
2012 6
2013 4
2014 7
2015 6
2016 5
2017 9
2018 7
2019 11
2020 11
2021 8
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33547213

98 results
Results by year
Filters applied: . Clear all
Page 1
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, Toulgoat F, Masson D, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. J Nucl Med. 2021 Sep 1;62(9):1221-1227. doi: 10.2967/jnumed.120.252791. Epub 2021 Feb 5. J Nucl Med. 2021. PMID: 33547213
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, Rohmer V, Couturier O, Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F. Bodet-Milin C, et al. J Nucl Med. 2016 Oct;57(10):1505-1511. doi: 10.2967/jnumed.116.172221. Epub 2016 May 26. J Nucl Med. 2016. PMID: 27230928 Free article. Clinical Trial.
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
Touchefeu Y, Bailly C, Frampas E, Eugène T, Rousseau C, Bourgeois M, Bossard C, Faivre-Chauvet A, Rauscher A, Masson D, David A, Cerato E, Carlier T, Sharkey RM, Goldenberg DM, Barbet J, Kraeber-Bodere F, Bodet-Milin C. Touchefeu Y, et al. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):874-882. doi: 10.1007/s00259-020-04989-3. Epub 2020 Aug 21. Eur J Nucl Med Mol Imaging. 2021. PMID: 32820369
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Rousseau C, Goldenberg DM, Colombié M, Sébille JC, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, Rauscher A, Fleury V, Labbe C, Chauvet AF, Fresnel JS, Toquet C, Barbet J, Sharkey RM, Campion L, Kraeber-Bodéré F. Rousseau C, et al. J Nucl Med. 2020 Aug;61(8):1205-1211. doi: 10.2967/jnumed.119.236000. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169921 Free PMC article. Clinical Trial.
Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.
Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, Martínez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, Navarro-González E. Romero-Lluch AR, et al. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2004-2013. doi: 10.1007/s00259-017-3759-4. Epub 2017 Jun 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28646462
Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, Lisinen I, Ahonen A, Heiskanen I, Väisänen M, Arola J, Korsoff P, Ebeling T, Sane T, Minn H, Välimäki MJ, Nuutila P. Kauhanen S, et al. J Nucl Med. 2011 Dec;52(12):1855-63. doi: 10.2967/jnumed.111.094771. Epub 2011 Nov 3. J Nucl Med. 2011. PMID: 22052128 Free article. Clinical Trial.
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, Faivre-Chauvet A, Barbet J, Rousseau C, Kraeber-Bodéré F. Bodet-Milin C, et al. Front Med (Lausanne). 2019 Jun 4;6:124. doi: 10.3389/fmed.2019.00124. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31214593 Free PMC article. Review.
F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, Deandreis D, Grimaldi S, Lumbroso J, Berdelou A, Hadoux J, Hescot S, Hartl D, Baudin E, Schlumberger M, Leboulleux S. Terroir M, et al. Thyroid. 2019 Oct;29(10):1457-1464. doi: 10.1089/thy.2018.0351. Thyroid. 2019. PMID: 31530235
98 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page